{"title": "PDF", "author": "PDF", "url": "https://classic.clinicaltrials.gov/ProvidedDocs/36/NCT03703336/Prot_000.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "RESEARCH PROTOCOL OF VACCINE CLINICAL TRIAL A PHASE III, RANDOMIZED, PARTIALLY DOUBLE- BLIND, ACTIVE CONTROL STUDY TO COMPARE THE IMMUNOGENICITY AND SAFETY OF A LIQUID FORMULATION OF ROTAVIN WITH THE CURRENTLY LICENSED FROZEN FORMULATION OF THE VACCINE (ROTAVIN-M1), IN HEALTHY VIETNAMESE INFANTS. Protocol NAME: Phase III Bridging Study Liquid Formulation of R OTAVIN Principal Investigator: NIHE Co-Principal Investigator : NIHE Investigator's Institution : National Institute of Hygiene and Epidemiology, Vietnam Sponsor: Center for Research and Production of Vaccines and Bio logicals (POLYVAC), Vietnam In Collaboration with: PATH, USA Manufacturer: Center for Research and Production of Vaccines an d Biologicals (POLYVAC), Vietnam Authority Agency: Ministry of Health, Vietnam Planned time: 4th quarter 2018 Total budget: From Government budget for Science and Technology: 0 VND From PATH: Approximately 8.5 billion VND Confidentiality Statement This document is confidential and is to be distributed for revi ew only to investigators, potential investigators, consultants, study staff, and applicab le independent ethics committees or institutional review boards. The contents of thi s document shall not be disclosed to others without written authorization from PATH (or others, as applicable), unless it is necessary to obtain informed consent from potentia l Investigator Head, Center for Clinical Trials , NIHEPrincipal Investigator Time rotavirus disease \u0003among children <5 years of body temperature of Monkey during the stud y Vaccine Weight (kg) Temperature (oC) Pre injection Post injection Pre injection mulatta monkey 6 -17 months consumption per week per rabbit Study group Week Average food consumption (g) p value Vaccine groups Body temperature: \u00037KH\u0003DYHUDJH\u0003WHPSHUDWXUH\u0003RI\u0003WKH\u0003\u0017\u0003JURXSV\u0003ZDV\u0003IRXQG\u0003WR\u0003EH\u0003UHODWL YHO\\\u0003VLPLODU\u0003 DQG\u0003ZLWKLQ\u0003WKH\u0003OLPLWV\u0011\u0003 Figure 2.3: Monitoring average body temperature rise of rabbit i n 4 groups. Hematology *URXS\u0015 *URXS\u0016 *URXS\u0017 CHART OF 2 Placebo-Dose1 Placebo-Dose 2 \u0013\u0015\u0017\u0019\u001b\u0014\u0013\u0014\u0015\u0014\u0017\u0014\u0019\u0014\u001b\u0015\u0013Percent children with symptoms (%)Vaccine - Dose 1 Vaccine - Dose 2 Placebo - Dose 1 Placebo - of IgA antibody at 1 month after the second oral dose Site Vaccine Placebo P Geometric Mean Concentration (GMC) before and aft er the administration of vaccine/placebo at levels of c hildren before administration of vaccine/placebo in ROTAVIN-M1 and Rot arix group at different time points (prior to study enrollment -M0, 3 and 12 months after the first dose participants with Rota IgA antibody positive one year after the \u0003RI\u0003WKH\u0003ODVW\u0003SDUWLFLSDQW\u0003LQ\u0003WKH\u0003WULDO\u000f\u0003 DFFRUGLQJ\u0003WR\u0003WKH\u0003WULDO\u0003VFKHPH\u0011\u0003 8\u0003STUDY EVALUATIONS at least a ratio > 0.5 of anti-rotavi rus IgA GMCs between ROTAVIN liquid formulation and ROTAVIN-M1 groups 28 days after the second dose, based on various group sizes and different assumed SD of log10 Ig A antibody concentrations Assumed SD of log10 IgA antibody concentrationsNumber of evaluable participants SHU group (ROTAVIN liquid formulation vs. ROTAVIN-M1)Power to detect at least a 0.5 ratio of anti-rotavirus IgA GMC s between ROTAVIN difference in percentage of participants with solicited post- vaccination reaction after each vaccination between ROTAVIN liqu id formulation and ROTAVIN-M1 groups can be detected with 90% power \u0003 Expected percentage of participant s with a solicited post-vaccination react ion in ROTAVIN- M1 groupNumber of vaccinated participant s per group (ROTAVIN liquid formulation vs. ROTAVIN- M1)Minimum difference in percentage of participa nts with a solicited post- vaccination reaction between the groups which can be detected 90% power \u0014\b\u0003 HQVXUH\u0003WKH\u0003EHVW\u0003SURWHFWLRQ\u0003IRU\u0003VWXG\\\u0003SDUWLFLSDQWV\u0011\u0003\u0003 15.2\u0003Study "}